Myriocin, a serine palmitoyltransferase inhibitor, suppresses tumor growth in a murine melanoma model by inhibiting de novo sphingolipid synthesis

References

• Lee YS, Choi KM, Choi MH, Ji SY, Lee S, Sin DM, et al. Serine palmitoyltransferase inhibitor myriocin induces growth inhibition of B16F10 melanoma cells through G(2) /M phase arrest. Cell Prolif 2011; 44:320 - 9; http://dx.doi.org/10.1111/j.1365-2184.2011.00761.x; PMID: 21645154
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277 - 300; http://dx.doi.org/10.3322/caac.20073; PMID: 20610543
   PubMed Web of Science ®Google Scholar
• Flaherty KT. Next generation therapies change the landscape in melanoma. F1000. Med-Rep 2011; 3:8
   Google Scholar
• Helmbach H, Rossmann E, Kern MA, Schadendorf D. Drug-resistance in human melanoma. Int J Cancer 2001; 93:617 - 22; http://dx.doi.org/10.1002/ijc.1378; PMID: 11477569
   PubMed Web of Science ®Google Scholar
• Soengas MS, Capodieci P, Polsky D, Mora J, Esteller M, Opitz-Araya X, et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 2001; 409:207 - 11; http://dx.doi.org/10.1038/35051606; PMID: 11196646
   PubMed Web of Science ®Google Scholar
• Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007; 445:851 - 7; http://dx.doi.org/10.1038/nature05661; PMID: 17314971
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Moschos S, Wang W. Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations. Clin Cancer Res 2006; 12:2331s - 6s; http://dx.doi.org/10.1158/1078-0432.CCR-05-2538; PMID: 16609054
   PubMed Web of Science ®Google Scholar
• Legha SS, Gianan MA, Plager C, Eton OE, Papadopoulous NE. Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma. Cancer 1996; 77:89 - 96; http://dx.doi.org/10.1002/(SICI)1097-0142(19960101)77:1<89::AID-CNCR15>3.0.CO;2-4; PMID: 8630945
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949 - 54; http://dx.doi.org/10.1038/nature00766; PMID: 12068308
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507 - 16; http://dx.doi.org/10.1056/NEJMoa1103782; PMID: 21639808
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711 - 23; http://dx.doi.org/10.1056/NEJMoa1003466; PMID: 20525992
   PubMed Web of Science ®Google Scholar
• Kluepfel D, Bagli J, Baker H, Charest MP, Kudelski A. Myriocin, a new antifungal antibiotic from Myriococcum albomyces. J Antibiot (Tokyo) 1972; 25:109 - 15; PMID: 5034807
   PubMed Web of Science ®Google Scholar
• Craveri R, Manachini PL, Aragozzini F. Thermozymocidin new antifungal antibiotic from a thermophilic eumycete. Experientia 1972; 28:867 - 8; http://dx.doi.org/10.1007/BF01923181; PMID: 4658889
   PubMedGoogle Scholar
• Fujita T, Inoue K, Yamamoto S, Ikumoto T, Sasaki S, Toyama R, et al. Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J Antibiot (Tokyo) 1994; 47:208 - 15; PMID: 8150717
   PubMed Web of Science ®Google Scholar
• Yu J, Xu H, Mo Z, Zhu H, Mao X. Determination of myriocin in natural and cultured Cordyceps cicadae using 9-fluorenylmethyl chloroformate derivatization and high-performance liquid chromatography with UV-detection. Anal Sci 2009; 25:855 - 9; http://dx.doi.org/10.2116/analsci.25.855; PMID: 19609022
   PubMed Web of Science ®Google Scholar
• Yoshikawa M, Yokokawa Y, Okuno Y, Yagi N, Murakami N. Synthesis of new immunosuppressive myriocin analogs, 2-epi-myriocin, 14-deoxomyriocin, Z-14-deoxomyriocin, and nor-deoxomyriocins: their structure-activity relationships. Chem Pharm Bull (Tokyo) 1994; 42:2662 - 4; PMID: 7697780
   PubMed Web of Science ®Google Scholar
• Miyake Y, Kozutsumi Y, Nakamura S, Fujita T, Kawasaki T. Serine palmitoyltransferase is the primary target of a sphingosine-like immunosuppressant, ISP-1/myriocin. Biochem Biophys Res Commun 1995; 211:396 - 403; http://dx.doi.org/10.1006/bbrc.1995.1827; PMID: 7794249
   PubMed Web of Science ®Google Scholar
• Park TS, Panek RL, Mueller SB, Hanselman JC, Rosebury WS, Robertson AW, et al. Inhibition of sphingomyelin synthesis reduces atherogenesis in apolipoprotein E-knockout mice. Circulation 2004; 110:3465 - 71; http://dx.doi.org/10.1161/01.CIR.0000148370.60535.22; PMID: 15545514
   PubMed Web of Science ®Google Scholar
• Hojjati MR, Li Z, Zhou H, Tang S, Huan C, Ooi E, et al. Effect of myriocin on plasma sphingolipid metabolism and atherosclerosis in apoE-deficient mice. J Biol Chem 2005; 280:10284 - 9; http://dx.doi.org/10.1074/jbc.M412348200; PMID: 15590644
   PubMed Web of Science ®Google Scholar
• Glaros EN, Kim WS, Wu BJ, Suarna C, Quinn CM, Rye KA, et al. Inhibition of atherosclerosis by the serine palmitoyl transferase inhibitor myriocin is associated with reduced plasma glycosphingolipid concentration. Biochem Pharmacol 2007; 73:1340 - 6; http://dx.doi.org/10.1016/j.bcp.2006.12.023; PMID: 17239824
   PubMed Web of Science ®Google Scholar
• Glaros EN, Kim WS, Quinn CM, Jessup W, Rye KA, Garner B. Myriocin slows the progression of established atherosclerotic lesions in apolipoprotein E gene knockout mice. J Lipid Res 2008; 49:324 - 31; http://dx.doi.org/10.1194/jlr.M700261-JLR200; PMID: 17978313
   PubMed Web of Science ®Google Scholar
• Futerman AH, Hannun YA. The complex life of simple sphingolipids. EMBO Rep 2004; 5:777 - 82; http://dx.doi.org/10.1038/sj.embor.7400208; PMID: 15289826
   PubMed Web of Science ®Google Scholar
• Pettus BJ, Bielawska A, Subramanian P, Wijesinghe DS, Maceyka M, Leslie CC, et al. Ceramide 1-phosphate is a direct activator of cytosolic phospholipase A2. J Biol Chem 2004; 279:11320 - 6; http://dx.doi.org/10.1074/jbc.M309262200; PMID: 14676210
   PubMed Web of Science ®Google Scholar
• Modrak DE, Gold DV, Goldenberg DM. Sphingolipid targets in cancer therapy. Mol Cancer Ther 2006; 5:200 - 8; http://dx.doi.org/10.1158/1535-7163.MCT-05-0420; PMID: 16505092
   PubMed Web of Science ®Google Scholar
• Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004; 4:604 - 16; http://dx.doi.org/10.1038/nrc1411; PMID: 15286740
   PubMed Web of Science ®Google Scholar
• Kok JW, Sietsma H. Sphingolipid metabolism enzymes as targets for anticancer therapy. Curr Drug Targets 2004; 5:375 - 82; http://dx.doi.org/10.2174/1389450043345452; PMID: 15134220
   PubMed Web of Science ®Google Scholar
• Knapp P, Baranowski M, Knapp M, Zabielski P, Blachnio-Zabielska AU, Gorski J. Altered sphingolipid metabolism in human endometrial cancer. Prostaglandins Other Lipid Mediat 2010; 92:62 - 6; http://dx.doi.org/10.1016/j.prostaglandins.2010.03.002; PMID: 20226264
   PubMed Web of Science ®Google Scholar
• Schiffmann S, Sandner J, Birod K, Wobst I, Angioni C, Ruckhaberle E, et al. Ceramide synthases and ceramide levels are increased in breast cancer tissue. Carcinogenesis 2009; 30:745 - 52; http://dx.doi.org/10.1093/carcin/bgp061; PMID: 19279183
   PubMed Web of Science ®Google Scholar
• Koyanagi S, Kuga M, Soeda S, Hosoda Y, Yokomatsu T, Takechi H, et al. Elevation of de novo ceramide synthesis in tumor masses and the role of microsomal dihydroceramide synthase. Int J Cancer 2003; 105:1 - 6; http://dx.doi.org/10.1002/ijc.11024; PMID: 12672022
   PubMed Web of Science ®Google Scholar
• Bensaad K, Vousden KH. p53: new roles in metabolism. Trends Cell Biol 2007; 17:286 - 91; http://dx.doi.org/10.1016/j.tcb.2007.04.004; PMID: 17481900
   PubMed Web of Science ®Google Scholar
• Hussain SP, Harris CC. p53 biological network: at the crossroads of the cellular-stress response pathway and molecular carcinogenesis. J Nihon Med Sch 2006; 73:54 - 64; http://dx.doi.org/10.1272/jnms.73.54; PMID: 16641528
   PubMedGoogle Scholar
• Zhu BS, Xing CG, Lin F, Fan XQ, Zhao K, Qin ZH. Blocking NF-kappaB nuclear translocation leads to p53-related autophagy activation and cell apoptosis. World J Gastroenterol 2011; 17:478 - 87; http://dx.doi.org/10.3748/wjg.v17.i4.478; PMID: 21274377
   PubMed Web of Science ®Google Scholar
• Sonnemann J, Palani CD, Wittig S, Becker S, Eichhorn F, Voigt A, et al. Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells. Eur J Cancer 2011; In press http://dx.doi.org/10.1016/j.ejca.2011.01.015; PMID: 21334198
   PubMed Web of Science ®Google Scholar
• Schwartz GK. Development of cell cycle active drugs for the treatment of gastrointestinal cancers: a new approach to cancer therapy. J Clin Oncol 2005; 23:4499 - 508; http://dx.doi.org/10.1200/JCO.2005.18.341; PMID: 16002840
   PubMed Web of Science ®Google Scholar
• Fingar DC, Blenis J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004; 23:3151 - 71; http://dx.doi.org/10.1038/sj.onc.1207542; PMID: 15094765
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999; 13:1501 - 12; http://dx.doi.org/10.1101/gad.13.12.1501; PMID: 10385618
   PubMed Web of Science ®Google Scholar
• Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene 2001; 20:1803 - 15; http://dx.doi.org/10.1038/sj.onc.1204252; PMID: 11313928
   PubMed Web of Science ®Google Scholar
• Pines J, Hunter T. Isolation of a human cyclin cDNA: evidence for cyclin mRNA and protein regulation in the cell cycle and for interaction with p34cdc2. Cell 1989; 58:833 - 46; http://dx.doi.org/10.1016/0092-8674(89)90936-7; PMID: 2570636
   PubMed Web of Science ®Google Scholar
• Villani MG, Appierto V, Cavadini E, Bettiga A, Prinetti A, Clagett-Dame M, et al. 4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines. Cancer Res 2006; 66:3238 - 47; http://dx.doi.org/10.1158/0008-5472.CAN-05-3362; PMID: 16540676
   PubMed Web of Science ®Google Scholar
• Sala G, Minutolo F, Macchia M, Sacchi N, Ghidoni R. Resveratrol structure and ceramide-associated growth inhibition in prostate cancer cells. Drugs Exp Clin Res 2003; 29:263 - 9; PMID: 15134383
   PubMedGoogle Scholar
• Devalapally H, Duan Z, Seiden MV, Amiji MM. Paclitaxel and ceramide co-administration in biodegradable polymeric nanoparticulate delivery system to overcome drug resistance in ovarian cancer. Int J Cancer 2007; 121:1830 - 8; http://dx.doi.org/10.1002/ijc.22886; PMID: 17557285
   PubMed Web of Science ®Google Scholar
• Schmelz EM, Dillehay DL, Webb SK, Reiter A, Adams J, Merrill AH Jr.. Sphingomyelin consumption suppresses aberrant colonic crypt foci and increases the proportion of adenomas versus adenocarcinomas in CF1 mice treated with 1,2-dimethylhydrazine: implications for dietary sphingolipids and colon carcinogenesis. Cancer Res 1996; 56:4936 - 41; PMID: 8895747
   PubMed Web of Science ®Google Scholar
• Dillehay DL, Webb SK, Schmelz EM, Merrill AH Jr.. Dietary sphingomyelin inhibits 1,2-dimethylhydrazine-induced colon cancer in CF1 mice. J Nutr 1994; 124:615 - 20; PMID: 8169652
   PubMed Web of Science ®Google Scholar
• Zhang P, Li B, Gao S, Duan RD. Dietary sphingomyelin inhibits colonic tumorigenesis with an up-regulation of alkaline sphingomyelinase expression in ICR mice. Anticancer Res 2008; 28:3631 - 5; PMID: 19189644
   PubMed Web of Science ®Google Scholar
• McGowan CH, Russell P. Human Wee1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr15. EMBO J 1993; 12:75 - 85; PMID: 8428596
   PubMed Web of Science ®Google Scholar
• Struckhoff AP, Patel B, Beckman BS. Inhibition of p53 sensitizes MCF-7 cells to ceramide treatment. Int J Oncol 2010; 37:21 - 30; PMID: 20514393
   PubMed Web of Science ®Google Scholar